Apexigen starts dosing in Phase Ib/II combination trial for solid tumours

Apexigen has started dosing patients in a Phase Ib/II clinical trial of APX005M in combination with Bristol-Myers Squibb ’s Opdivo (nivolumab) to treat patients with advanced solid tumours.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news